Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant
Magenta Therapeutics, Inc. (MGTA)
Last magenta therapeutics, inc. earnings: 11/13 08:00 am
Check Earnings Report
Company Research
Source: Business Wire
-- A single dose of MGTA-145 plus plerixafor mobilized two to three times more stem cells in non-human primates than multi-day regimen of current standard of care G-CSF -- -- Cells mobilized with MGTA-145 plus plerixafor rapidly engrafted in non-human primates following autologous transplant -- -- MGTA-145-mobilized cells from non-human primates suppressed GvHD and extended survival in preclinical models -- -- MGTA-145 to enter the clinic in the first half of 2019 -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company presented new preclinical research on its MGTA-145 product candidate for stem cell mobilization at the Transplant and Cellular Therapy (TCT) annual meeting. Magenta is deve
Show less
Read more
Impact Snapshot
Event Time:
MGTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTA alerts
High impacting Magenta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MGTA
News
- Magenta Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/MGTA/price-target/">NASDAQ: MGTA</a>) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $19.00 price target on the stock.MarketBeat
- Magenta Therapeutics Reports Third Quarter Financial Results and Program HighlightsBusiness Wire
- Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual MeetingBusiness Wire
- Magenta Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/MGTA/price-target/">NASDAQ: MGTA</a>) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.MarketBeat
- Magenta Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/MGTA/price-target/">NASDAQ: MGTA</a>) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.25 priceMarketBeat
MGTA
Earnings
- 11/4/21 - Beat
MGTA
Sec Filings
- 11/4/21 - Form 10-Q
- 11/4/21 - Form 8-K
- 10/4/21 - Form 4
- MGTA's page on the SEC website